LONDON (Alliance News) - Motif Bio PLC said Thursday it is exploring options, including strategic partnerships, grant funding, or potentially market funding, in order to support phase III trials of its lead antibiotic iclaprim.
The company will present at the BioEquity Europe conference in Austria later this month. BioEquity is an industry event for financial dealmakers.
"We are delighted to have been selected to present at the prestigious BioEquity Europe 2015 conference. Motif is determined to maximize shareholder value by seeking funding with the lowest cost of capital," said Chief Executive Officer Graham Lumsden in a statement.
Shares in Motif Bio are trading down 1.7% at 31.45 pence Thursday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
